- Home
- PIII vs LGVN Comparison
PIII vs LGVN Comparison
Compare PIII & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- LGVN
- Stock Information
- Founded
- PIII 2015
- LGVN 2014
- Country
- PIII United States
- LGVN United States
- Employees
- PIII N/A
- LGVN N/A
- Industry
- PIII Medical/Nursing Services
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- PIII Health Care
- LGVN Health Care
- Exchange
- PIII Nasdaq
- LGVN Nasdaq
- Market Cap
- PIII 30.8M
- LGVN 27.6M
- IPO Year
- PIII N/A
- LGVN 2021
- Fundamental
- Price
- PIII $0.18
- LGVN $1.50
- Analyst Decision
- PIII Hold
- LGVN Strong Buy
- Analyst Count
- PIII 2
- LGVN 3
- Target Price
- PIII $0.25
- LGVN $8.67
- AVG Volume (30 Days)
- PIII 710.9K
- LGVN 201.4K
- Earning Date
- PIII 03-27-2025
- LGVN 05-13-2025
- Dividend Yield
- PIII N/A
- LGVN N/A
- EPS Growth
- PIII N/A
- LGVN N/A
- EPS
- PIII N/A
- LGVN N/A
- Revenue
- PIII $1,500,455,000.00
- LGVN $2,392,000.00
- Revenue This Year
- PIII $21.45
- LGVN $26.05
- Revenue Next Year
- PIII N/A
- LGVN $12.27
- P/E Ratio
- PIII N/A
- LGVN N/A
- Revenue Growth
- PIII 18.48
- LGVN 237.38
- 52 Week Low
- PIII $0.15
- LGVN $0.77
- 52 Week High
- PIII $0.89
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- PIII 45.80
- LGVN 48.73
- Support Level
- PIII $0.16
- LGVN $1.44
- Resistance Level
- PIII $0.20
- LGVN $1.92
- Average True Range (ATR)
- PIII 0.02
- LGVN 0.12
- MACD
- PIII 0.00
- LGVN -0.01
- Stochastic Oscillator
- PIII 49.57
- LGVN 37.71
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.